Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariaelena Pierobon

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
Proteomics|October 15, 2014
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapyMaria Isabella Sereni, Elisa Baldelli, Guido Gambara, et al.
Cell Communication and Signaling : CCS|January 16, 2026
Interruption of cross-communication pathways alters the immune cell signature of pancreatic cancer and decreases tumor growthJill P Smith, Mahdis Mohit, Joi Kenner, et al.
BMC Medicine|September 13, 2018
An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver diseaseZobair M Younossi, Azza Karrar, Mariaelena Pierobon, et al.
British Journal of Cancer|July 1, 2017
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancersMaria Isabella Sereni, Elisa Baldelli, Guido Gambara, et al.
Research Square|November 14, 2023
Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant CancersKris Wood, Daniel Nussbaum, Colin Martz, et al.
Molecular Cancer Research : MCR|October 12, 2021
Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling PathwayAisha Naeem, Varsha Harish, Sophie Coste, et al.
NPJ Precision Oncology|February 16, 2023
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancersMaysa M Abu-Khalaf, K Alex Hodge, Christos Hatzis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2012
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mappingJulia D Wulfkuhle, Daniela Berg, Claudia Wolff, et al.
Molecular Cancer Therapeutics|March 5, 2022
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell CarcinomaSehrish Javaid, Antje Schaefer, Craig M Goodwin, et al.
Cancer Research|December 18, 2021
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy InhibitorsClint A Stalnecker, Kajal R Grover, A Cole Edwards, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Proteomics|October 15, 2014
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapyMaria Isabella Sereni, Elisa Baldelli, Guido Gambara, et al.
Cell Communication and Signaling : CCS|January 16, 2026
Interruption of cross-communication pathways alters the immune cell signature of pancreatic cancer and decreases tumor growthJill P Smith, Mahdis Mohit, Joi Kenner, et al.
BMC Medicine|September 13, 2018
An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver diseaseZobair M Younossi, Azza Karrar, Mariaelena Pierobon, et al.
British Journal of Cancer|July 1, 2017
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancersMaria Isabella Sereni, Elisa Baldelli, Guido Gambara, et al.
Research Square|November 14, 2023
Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant CancersKris Wood, Daniel Nussbaum, Colin Martz, et al.
Molecular Cancer Research : MCR|October 12, 2021
Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling PathwayAisha Naeem, Varsha Harish, Sophie Coste, et al.
NPJ Precision Oncology|February 16, 2023
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancersMaysa M Abu-Khalaf, K Alex Hodge, Christos Hatzis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2012
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mappingJulia D Wulfkuhle, Daniela Berg, Claudia Wolff, et al.
Molecular Cancer Therapeutics|March 5, 2022
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell CarcinomaSehrish Javaid, Antje Schaefer, Craig M Goodwin, et al.
Cancer Research|December 18, 2021
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy InhibitorsClint A Stalnecker, Kajal R Grover, A Cole Edwards, et al.
Pageof 10